Eye herpes is not rare: research and clinical series consistently identify herpes simplex virus as the leading infectious cause of corneal blindness in high-income countries, and population surveys show that a large share of adults carry the virus in a latent state that can reactivate in the eye. Most people never develop eye disease, but the pool of people at risk is enormous because the virus is endemic worldwide.

The term covers several distinct conditions, and conflating them distorts the numbers. Herpes keratitis affects the clear front surface of the eye. Herpetic uveitis inflames structures inside the eye. Herpes zoster ophthalmicus is a different virus affecting a nerve branch and the eye surface. Each has its own frequency, its own triggers, and its own prognosis.

What the virus does inside a nerve

Herpes simplex virus type 1 spreads by direct contact with oral secretions, usually in childhood. It enters sensory nerve endings in the mouth or skin and travels to the trigeminal ganglion, a bundle of nerve cell bodies beside the brain. There it establishes latency: viral DNA persists inside neurons without producing infectious particles or symptoms.

The virus reactivates when immune surveillance weakens locally or systemically. Sunlight, fever, psychological stress, menstruation, and eye surgery are commonly reported triggers, though the evidence for each varies. Reactivated virus travels back down the same nerve branch and can reach the cornea, the conjunctiva, or the eyelids.

The eye is vulnerable because the cornea is densely innervated and immunologically unusual. It has no blood vessels in its center, so immune cells arrive slowly. That delay lets the virus replicate on the surface before defenses engage, which is why corneal disease can appear abruptly.

A plain-language version: the virus hides in a nerve, wakes up under certain pressures, and follows the nerve back to the eye surface.

How frequently eye herpes occurs

Precise population rates are hard to establish because surveillance is fragmented. What is well documented is the underlying exposure. World Health Organization estimates indicate that roughly two-thirds of the global population under age 50 is infected with HSV-1, which is hundreds of millions of people. Most carry it orally and never have eye symptoms.

Eye disease is a small fraction of that total. Clinical and epidemiologic reviews of herpes keratitis place incidence in high-income countries at roughly 10 to 30 new cases per 100,000 people per year, with recurrence being the dominant long-term problem. Recurrence is where the real burden sits: studies of herpes keratitis report that a substantial proportion of patients experience at least one recurrence within a few years, and each episode adds risk to the cornea.

Numbers to anchor the scale:

HSV-1 prevalence: approximately two-thirds of adults under 50 globally, per WHO. Herpes keratitis incidence: commonly cited at roughly 10 to 30 per 100,000 person-years in high-income settings. Recurrence: frequent enough that long-term follow-up is standard practice in ophthalmology. Herpetic eye disease is the most common infectious cause of corneal blindness in high-income countries. HSV-2 can also infect the eye, mainly through neonatal exposure during delivery.

The exact incidence figures vary by study design and case definition, so treat them as order-of-magnitude estimates rather than precise counts. What is consistent across sources is the ranking: herpes simplex is the leading infectious corneal threat in countries where trachoma and onchocerciasis have been controlled.

When the numbers mislead

Statistics on eye herpes usually count clinic cases, and clinic cases are not the same as all infections. Mild epithelial keratitis may resolve without a specialist ever seeing it, so documented rates likely undercount total episodes. Conversely, severe cases are overrepresented in hospital-based series, which inflates perceived severity.

Neonatal herpes is a separate and much rarer category, but it is the most dangerous. When a mother sheds HSV near delivery, the newborn can acquire infection of the eye, skin, or central nervous system. Neonatal HSV disease is uncommon, but ocular involvement occurs in a meaningful share of neonatal cases and requires urgent treatment. The rarity of neonatal eye herpes does not make it less urgent.

Geographic variation matters too. HSV-1 exposure rises with age and varies with sanitation, crowding, and oral contact patterns. Rates of eye disease track those exposure patterns imperfectly, because host immunity and access to care shape whether an infection becomes a recorded case.

The counterintuitive detail: most people carrying HSV-1 in the trigeminal nerve will never have an eye episode. The virus is common; the eye disease is the exception, not the rule.

Misconceptions that distort risk perception

Several false beliefs circulate widely and change how people act.

First, people assume eye herpes is sexually transmitted. HSV-1 eye disease is usually acquired orally in childhood, not through sexual contact. HSV-2 can affect the eye, but it is a minority of ocular cases.

Second, people assume a red, irritated eye is either allergy or infection and cannot be herpes. Herpes keratitis can look like a simple conjunctivitis at first. The distinguishing features, such as a branching corneal lesion visible on slit-lamp examination, require an eye exam.

Third, people assume a single episode means lifelong severe disease. Many first episodes resolve with treatment and never recur. Others recur and require long-term management because each recurrence can scar the cornea.

Fourth, people assume the antiviral used for cold sores is adequate for the eye. Topical and oral antivirals used for skin lesions are not automatically appropriate for corneal disease, and self-treating an eye with skin creams is harmful.

Fifth, people assume herpes zoster ophthalmicus and herpes simplex eye disease are interchangeable. They involve different viruses, different age profiles, and different treatment durations.

Comparing the main ocular herpes syndromes

Condition Virus Typical age group Main eye risk Recurrence pattern
Epithelial keratitis HSV-1 (mostly) Children and adults Surface breakdown, healing with treatment Can recur, often with triggers
Stromal keratitis HSV-1 Adults Corneal scarring, vision loss Chronic, immune-driven, recurring
Herpetic uveitis HSV-1, HSV-2 Adults Internal inflammation, pressure rise Recurrent, needs specialist care
Herpes zoster ophthalmicus Varicella-zoster Older adults, immunocompromised Nerve pain, corneal and lid involvement Usually one episode, complications persist
Neonatal ocular herpes HSV-1 or HSV-2 Newborns Severe, disseminated risk Depends on treatment timing

Reading the table plainly: these are different diseases sharing a family name, and their frequencies cannot be pooled into a single eye herpes rate.

What a clinical course looks like

The timeline below reflects the general pattern of herpes simplex eye disease, not a fixed schedule. Individual courses vary, and only an eye care professional can assess a specific eye.

Stage Typical timing What happens
Primary infection Childhood, often unnoticed Virus enters oral tissue, travels to trigeminal ganglion
Latency Months to decades Viral DNA persists in nerve cells without symptoms
Reactivation Variable Virus travels back to the eye surface, replication begins
First episode Days after reactivation Redness, tearing, light sensitivity, foreign-body sensation
Diagnosis Within days if evaluated Slit-lamp exam identifies characteristic corneal findings
Treatment course Days to weeks Antiviral therapy under professional supervision
Recurrence risk Months to years Repeat episodes possible, cumulative corneal damage
Long-term follow-up Years Monitoring for scarring, vision change, and complications

Practical actions and thresholds

The most useful practical advice concerns when to escalate, not how to self-treat.

Red-flag warning signs that warrant prompt professional evaluation:

A red eye with decreasing vision, not just irritation. Eye pain with light sensitivity that worsens rather than settles. A history of a prior herpes eye episode with new symptoms. A branching or dendritic corneal pattern noted by any examiner. Eye symptoms in a newborn or in a pregnant woman near delivery. A red eye after recent eye surgery or steroid use.

Care-seeking thresholds by scenario:

Any new painful red eye with vision change: same-day eye care. Recurrent episodes: establish a long-term plan with an ophthalmologist rather than episodic urgent care. Known trigger exposure with early symptoms: contact your eye care clinician before using any leftover medication. Neonatal exposure concern: immediate pediatric evaluation.

Self-management boundaries matter. Do not apply steroid drops without professional direction, because steroids can worsen active viral replication. Do not use oral antiviral medication intended for another person. Do not assume a resolving red eye is harmless if vision is affected.

Prevention is modest but real. Reducing direct oral contact with an active cold sore, avoiding sharing towels and utensils during outbreaks, and using sun protection around the eyes are reasonable low-cost steps, though evidence for each is limited.

What the numbers cannot tell you

The honest limit of this topic is that no single authoritative figure captures how common eye herpes is. Incidence estimates cluster around the ranges cited above, but definitions differ, case ascertainment differs, and many countries lack reliable surveillance.

Two other limits deserve emphasis. First, prevalence of HSV-1 infection is not prevalence of eye disease; conflating them inflates risk perception. Second, recurrence statistics come disproportionately from specialist clinics, which see the harder cases. A person with a single mild episode treated in primary care may never appear in those series.

What can be said with confidence: herpes simplex is a common, persistent viral infection; ocular involvement is uncommon relative to infection but common enough to be a leading infectious cause of corneal vision loss; and recurrence, not first infection, drives long-term harm. The practical takeaway follows from that: early professional evaluation of a painful red eye with vision change matters more than trying to estimate personal risk from population statistics.